Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Conditions
Keywords
leukemia, glutaminase, glutamine
Brief summary
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival. To exploit the dependence of tumors on glutamine, CB-839, a potent and selective inhibitor of the first enzyme in glutamine utilization, glutaminase, will be tested in this Phase 1 study in patients with leukemia. This study is an open-label Phase 1 evaluation of CB-839 in subjects with leukemia. Part 1 is a dose escalation study to identify the recommended Phase 2 dose as a single agent and in combination with azacitidine. Patients enrolled into Part 2 will be treated with the recommended Phase 2 dose. As an extension of Part 2, patients with relapsed/ refractory or newly diagnosed AML will be treated with CB-839 in combination with azacitidine. All patients will be assessed for safety, pharmacokinetics (plasma concentration of drug), pharmacodynamics (inhibition of glutaminase), biomarkers (biochemical markers that may predict responsiveness in later studies), and tumor response.
Interventions
DRUGCB-839
Single-agent CB-839
DRUGCB-Aza
CB-839 in combination with standard dose azacitidine
Sponsors
Calithera Biosciences, Inc
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of AML or ALL, relapsed or refractory after at least 1 prior treatment regimen. Newly-diagnosed patients ≥ 60 years old who have refused or are considered unfit for standard chemotherapy regimens or stem cell transplantation are also eligible. * Patients must have no available approved therapies that confer clinical benefit * All patients must have bone marrow involvement of their tumor, with documented blast percentage of \> 5%. * Peripheral blood blast count must be ≤ 30,000 cells/µL. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 * Adequate hepatic, renal, and cardiac function
Exclusion criteria
* Any other current malignancy * Patients with acute promyelocytic leukemia (APL) * Treatment with an unapproved, investigational agent within 21 days of the first dose of study drug * Allogeneic hematopoietic stem cell transplant or Donor Lymphocyte Infusion within 90 days prior to to the first dose of study drug * Active GVHD * Unable to receive medications by mouth * Major surgery within 28 days before Cycle 1 Day 1 * Uncontrolled, active infection; patients who are known to have HIV infection/ seropositivity, Hepatitis A, B, or C, or CMV reactivation * Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days prior to Day 1 * Refractory nausea and vomiting or other situation that may preclude adequate absorption * Conditions that could interfere with treatment and procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability of CB-839: Incidence of adverse events | Every 21 days from study start until disease progression or unacceptable toxicity, assessed an expected average of 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics: Area under the Curve (AUC) of CB-839 concentration in blood | Study Days 1, 15, and 22 |
| Pharmacodynamics: % inhibition of glutaminase in blood | Study Days 1 and 15 |
| Clinical Activity: % of Tumor Cells in Bone Marrow | Every 21 days from study start, assessed for an expected average of 6 months |
Countries
United States
Outcome results
None listed